Kemeruvir, 600 mg 60 pcs

Clinical and Pharmacological Group

Antiviral drug active against HIV

Pharmacotherapeutic group

Antiviral [HIV] medicine

Indications

Treatment of HIV infection in adults and children aged 6 years or older and weighing 20 kg or more who have previously received antiretroviral therapy (in combination with low-dose ritonavir and other antiretrovirals).

Active ingredient

How to take, the dosage

Ingestion. Darunavir should always be administered in combination with low-dose ritonavir as an agent to improve its pharmacokinetic characteristics, as well as in combination with other antiretroviral drugs. The possibility of prescribing ritonavir should be considered before starting therapy with darunavir/ritonavir.

After initiation of therapy with darunavir, patients should not change or discontinue therapy without consulting their physician.

The 75 mg and 150 mg dosages have been developed for pediatric use. In adults, these dosages require a large number of tablets to achieve therapeutic doses, which on the one hand make them difficult to swallow and on the other can cause allergic reactions due to increased intake of excipients contained in the tablets, so they should be used only when other dosages are not available.

Contraindications

* Hypersensitivity to darunavir or any of the drug components.

* Concomitant use with drugs that are metabolized primarily by cytochrome Р450 3A4 isoenzymes, and the increase in plasma concentrations of which is associated with the occurrence of serious and/or life-threatening side effects (narrow therapeutic range). These drugs include antihistamines (astemizole, terfenadine), alfuzosin, quetiapine, sildenafil (used to treat pulmonary arterial hypertension), rifampicin, sedatives/depressants (oral triazolam, midazolam), GI stimulants (cisapride), drugs drugs containing St. John’s Wort extract, ergot alkaloids (ergotamine, dihydroergotamine, ergometrine and methylergometrine), antiarrhythmic drugs (amiodarone, bepridil, quinidine, lidocaine for systemic use), HMG-CoA reductase inhibitors (simvastatin, lovastatin), neuroleptics (pimozide, sertindol). See also section “Interaction with other medicinal products”.

* Concurrent use with lopinavir/ritonavir combination.

* Severe hepatic impairment (Child-Pugh class C).

* Children under 6 years of age.

With caution

* Mild to moderate liver impairment (Child-Pugh class A and B)

* Allergy to sulfonamides

* Age over 65 years

* Concurrent use of drugs that bind highly to alpha1-acid glycoprotein.

* In patients with chronic hepatitis (including chronic viral hepatitis B and C).

* In patients with hemophilia.